![Mark J. Bamberger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Mark J.
Bamberger worked as the Director of Cardiovascular Disease Research at Pfizer Inc. from 2004 to 2008.
He also served as the Chief Scientific Officer at Stealth BioTherapeutics Corp.
from 2014 to 2020.
Bamberger received his undergraduate degree from St. Joseph's University in 1974 and his doctorate from Drexel University College of Medicine.
Anciens postes connus de Mark J. Bamberger
| Sociétés | Poste | Fin |
|---|---|---|
| STEALTH BIOTHERAPEUTICS CORP | Directeur Technique/Scientifique/R&D | 01/01/2020 |
| PFIZER INC. | Corporate Officer/Principal | 01/01/2008 |
Formation de Mark J. Bamberger
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
84
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
St. Joseph's University
 St. Joseph's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Drexel University College of Medicine
 Drexel University College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stealth BioTherapeutics Corp.
 Stealth BioTherapeutics Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops investigational drugs for the treatment of diseases involving mitochondrial dysfunction | Health Technology |
